MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Ipsen SA.

Avatud

SektorRahandus

96.85 0.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

96.1

Max

98.5

Põhinäitajad

By Trading Economics

Sissetulek

-118M

114M

Müük

71M

1.8B

P/E

Sektori keskmine

21.241

20.525

Dividenditootlus

1.54

Kasumimarginaal

6.249

Töötajad

5,358

EBITDA

228M

710M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+21.76% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.54%

4.36%

Turustatistika

By TradingEconomics

Turukapital

7.5B

Eelmine avamishind

96.12

Eelmine sulgemishind

96.85

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Ipsen SA. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ipsen SA. Prognoos

Hinnasiht

By TipRanks

21.76% tõus

12 kuu keskmine prognoos

Keskmine 119.75 EUR  21.76%

Kõrge 145 EUR

Madal 100 EUR

Põhineb 8 Wall Streeti analüütiku instrumendi Ipsen SA. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

3

Osta

4

Hoia

1

Müü

Tehniline skoor

By Trading Central

94.4 / 99.15Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.